<DOC>
	<DOCNO>NCT00775411</DOCNO>
	<brief_summary>The study evaluate safety efficacy intravitreal dexamethasone implant adjunctive therapy Anti-VEGF treatment study eye treatment naïve subject choroidal neovascularization secondary age-related macular degeneration . Subjects follow 26 week .</brief_summary>
	<brief_title>Safety Efficacy New Therapy Adjunctive Therapy Anti-vascular Endothelial Growth Factor ( Anti-VEGF ) Subjects With Wet Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>50 year age older active subfoveal choroidal neovascularization ( CNV ) secondary AMD Central retinal thickness ≥ 300 µm Visual acuity 20/400 20/32 Eligible AntiVEGF therapy Previous treatment CNV due AMD High eye pressure Glaucoma Uncontrolled systemic disease Known allergy study medication Recent eye surgery injection eye Female subject childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>